VTYX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Ventyx Biosciences Inc (VTYX) is not a good buy for a long-term beginner investor at this time. The stock is trading near its acquisition price of $14, and analysts have downgraded it to Neutral with no significant upside potential. Additionally, the company's financial performance is weak, and there are no positive catalysts or signals suggesting a strong entry point.
The technical indicators are mixed. While the moving averages are bullish (SMA_5 > SMA_20 > SMA_200), the MACD is negative (-0.132), and the RSI is neutral at 63.377. The stock is trading near its pivot point of 13.951, with limited movement expected due to the acquisition agreement.
Hedge funds have increased their buying activity by 427.27% over the last quarter.
Financial performance is weak, with declining net income (-35.24% YoY) and EPS (-36.00% YoY).
In Q3 2025, the company reported zero revenue growth (0.00% YoY), a net income loss of -$22.83M (-35.24% YoY), and a decline in EPS to -0.32 (-36.00% YoY). Gross margin remains at 0.
Analysts have downgraded the stock to Neutral from Overweight/Buy with a price target of $14, citing the acquisition agreement with Eli Lilly. There is no expected upside beyond the acquisition price.
